Bone Loss
IAS 2013: Second-line HIV Therapy with NRTIs Linked to Bone Loss [VIDEO]
- Details
- Category: Bone Loss
- Published on Sunday, 07 July 2013 00:00
- Written by Gregory Fowler
Bone loss occurs less often when people on failing antiretroviral therapy switch to a NRTI-sparing second-line regimen containing raltegravir, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
Bone Loss and Fracture Risk are 'Modest' among HIV+ People, Linked to Tenofovir, Smoking, and HCV
- Details
- Category: Bone Loss
- Published on Thursday, 06 June 2013 00:00
- Written by Liz Highleyman
Continued bone loss among HIV positive men with osteopenia was modest overall, but about 25% of those taking tenofovir (Viread, also in 4 antiretroviral coformulations) experienced significant loss, according to a recent study. A related meta-analysis found that HIV infection is associated with a modest likelihood of new fractures, with smoking and hepatitis C virus (HCV) coinfection further increasing the risk.
Study Finds Increased Fractures in First 2 Years after Starting Antiretroviral Treatment
- Details
- Category: HIV Treatment
- Published on Friday, 14 December 2012 00:00
- Written by Paul Dalton
HIV positive individuals appear to have significantly increased risk of bone fractures during the first 2 years after beginning antiretroviral therapy (ART), but the risk returned to baseline levels thereafter, according to a study published in the November 2012 issue of the journal AIDS.
HIV Treatment Interruption Associated with Reduced Bone Loss in SMART Trial
- Details
- Category: Bone Loss
- Published on Tuesday, 15 January 2013 00:00
- Written by Liz Highleyman
People who stopped antiretroviral therapy (ART) in the SMART trial had less bone loss and lower levels of bone metabolism biomarkers than people who remained on continuous treatment, according to a report in the January 8, 2013, advance edition of Journal of Bone Mineral Research.
ICAAC 2012: Simplified Abacavir/Atazanavir Combo Keeps HIV Suppressed, May Help Bones
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 10 October 2012 00:00
- Written by Liz Highleyman
Substituting abacavir/lamivudine (the drugs in Epzicom) for tenofovir/emtricitabine (the drugs in Truvada) and dropping the ritonavir (Norvir) booster with atazanavir (Reyataz) maintains undetectable HIV viral load and improves biomarkers of bone loss, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) last month in San Francisco.